PH response type nano antibacterial peptide with immunoregulation function as well as preparation method and application of pH response type nano antibacterial peptide

By designing pH-responsive nanopeptides and utilizing amino acid sequences and imidazole matrix protonation mechanisms, bactericidal effects in acidic environments and immunomodulation in neutral environments were achieved. This solved the problems of antimicrobial peptides accidentally killing beneficial bacteria and developing drug resistance, and demonstrated good biocompatibility and immunomodulatory functions.

CN118978602AActive Publication Date: 2024-11-19NORTHEAST AGRICULTURAL UNIVERSITY
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411020706.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-29
Publication Date
2024-11-19
Estimated Expiration
2044-07-29

AI Technical Summary

Technical Problem

Existing antimicrobial peptides have problems such as accidentally killing beneficial bacteria, disrupting the intestinal microecological environment, and drug resistance in clinical applications and livestock production, and bacterial resistance to them is difficult to avoid.

Method used

A pH-responsive antimicrobial nanopeptide with the amino acid sequence shown in SEQ ID No. 1 was designed. It self-assembles into a nano-network structure through acetylation of the N-terminus of 2-naphthoic acid and imidazole matrix protonation. It kills Gram-negative bacteria in acidic environments and captures pathogens and promotes macrophage phagocytosis in neutral environments.

Benefits of technology

It effectively kills Gram-negative bacteria in acidic environments, captures pathogens and promotes immune responses in neutral environments, reduces the development of drug resistance, maintains good biocompatibility, and avoids the overuse of antimicrobial peptides.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118978602A_ABST
    Figure CN118978602A_ABST
Patent Text Reader

Abstract

The invention provides a pH response type nano antibacterial peptide with an immunoregulation function and a preparation method and application thereof, and belongs to the technical field of biology, the sequence of the antibacterial peptide is shown as SEQ ID No.1, and the N end of the antibacterial peptide is acetylated through 2-naphthobutyric acid. The antibacterial peptide can be spontaneously assembled into a nano net structure, has a good killing effect on pathogenic bacteria, especially gram-negative bacteria, in an acidic environment with the pH value of 5.5, has good biocompatibility, captures the pathogenic bacteria although the antibacterial peptide does not have antibacterial activity when the pH value is 7.4, but can promote the phagocytosis of macrophages on cell clusters, so that the phagocytosis effect of the macrophages on the cell clusters is promoted, and the antibacterial peptide can be used for killing the pathogenic bacteria, especially gram-negative bacteria, in an acidic environment with the pH value of 5.5. The possibility that bacteria generate drug resistance is effectively reduced. In conclusion, the invention provides the pH response type nano antibacterial peptide with the immunoregulation function, which has great development potential and relatively high application value.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biotechnology, and specifically relates to a pH-responsive nano antimicrobial peptide with immunomodulatory function, and a preparation method and application thereof. Background Art

[0002] Antimicrobial peptides (AMPs), also known as host defense peptides, are an important part of the body's innate immune system. They are considered to be the most promising alternatives to antibiotics because of their membrane-breaking and bactericidal mechanisms that are not likely to cause bacterial resistance. Although antimicrobial peptides have shown incomparable superiority, they still face challenges in clinical application and animal husbandry production. On the one hand, traditional antimicrobial peptides often kill beneficial bacteria in the host due to their broad-spectrum antimicrobial activity, and also have a killing effect on normal microbial flora in the intestine, thereby destroying the balance of the intestinal microecological environment and inducing serious secondary infections. On the other hand, although bacteria are not easy to develop resistance to antimicrobial peptides, the resistance of antimicrobial peptides themselves cannot be ignored. Therefore, mobilizing the body's immune function to synergistically resist bacterial infection is an effective strategy. Due to the production of various acids by bacterial metabolism, the microenvironment at the lesion site is weakly acidic, which can easily cause changes in the structure of antimicrobial peptides and affect the antimicrobial activity. Therefore, the new design or molecular modification of existing natural antimicrobial peptides with pH-responsive targeted antimicrobial peptides is of great significance for solving the problem of drug resistance and finding alternatives to antibiotics. Summary of the invention

[0003] Based on the above background technical problems, the purpose of the present invention is to provide a pH-responsive self-assembling nano antimicrobial peptide with immunomodulatory function, which can spontaneously assemble into a nano-network structure, has a good killing effect on pathogens, especially Gram-negative bacteria, in an acidic environment of pH 5.5, and has good biocompatibility. Although it has no antibacterial activity at pH 7.4, it captures pathogens and promotes the phagocytosis of cell clusters by macrophages, effectively reducing the possibility of bacterial resistance.

[0004] The technical solution adopted by the present invention is as follows: a pH-responsive nano antimicrobial peptide with immunomodulatory function, whose amino acid sequence is shown in SEQ ID No. 1, and whose N-terminus is acetylated by 2-naphthylbutyric acid.

[0005] Furthermore, the pH-responsive nano antimicrobial peptide having immunomodulatory function as described above has a molecular formula as shown in formula (I):

[0006]

[0007]

[0008] Another object of the present invention is to provide a method for preparing the pH-responsive nano antimicrobial peptide having immunomodulatory function as described above, the steps of which are as follows:

[0009] S1: Alternately arrange polar uncharged phenylalanine and histidine with imidazole groups to obtain the sequence structural unit of FH and repeat it 6 times to construct a β-folded secondary structure with a hydrophilic-hydrophobic alternating mode. At physiological pH, the neutral imidazole group can act as both a hydrogen bond donor and a hydrogen bond acceptor, and can promote the self-assembly of peptide chain molecules into supramolecular nanostructures through hydrogen bonding with the hydrophobic amino acid phenylalanine to form a stable nanofiber structure; under weak acid pH conditions, the imidazole group undergoes H protonation, causing an increase in positive charge, and the positively charged polypeptide recognizes and is enriched on the surface of the negatively charged bacterial membrane, exerting antibacterial activity and forming a stable nanofiber structure; GGG is used as a flexible link to connect with the 5th to 13th active recognition region of ubiquitin VKTLTGKTI to construct a polypeptide sequence as shown in SEQ ID No. 1, and then its N-terminus is acetylated with 2-naphthoic acid to provide hydrophobic interaction as a hydrophobic scaffold;

[0010] S2: The peptide is synthesized by solid phase chemical synthesis, and then purified by chromatography and identified by mass spectrometry to complete the preparation of the peptide;

[0011] S3: The peptide was then subjected to nanomorphological characterization, biocompatibility, capture ability, antibacterial ability, and macrophage phagocytosis ability tests, and was finally named the antimicrobial peptide Nap-FH6-Ubi 5-13 .

[0012] Furthermore, the self-assembly conditions of the pH-responsive nano antimicrobial peptide with immunomodulatory function as described above are as follows: pH = 5.5, concentration 1-256 μM, incubation at 37°C for 24 hours or pH = 7.4, concentration 9-256 μM, incubation at 37°C for 24 hours.

[0013] Furthermore, the pH-responsive nano antimicrobial peptide with immunomodulatory function as described above can kill Escherichia coli or Salmonella typhimurium in an acidic environment of pH 5.5, and can capture Escherichia coli in an environment of pH 7.4.

[0014] Another object of the present invention is to provide the use of the above-mentioned pH-responsive nano antimicrobial peptide with immunomodulatory function in the preparation of drugs for treating and / or preventing infectious diseases caused by Gram-negative bacteria.

[0015] Furthermore, in the above application, the Gram-negative bacteria are Escherichia coli or Salmonella typhimurium.

[0016] The present invention also provides a drug suitable for treating and / or preventing Gram-positive bacteria infection, wherein the Gram-negative bacteria are Escherichia coli or Salmonella typhimurium, and the drug contains the pH-responsive nano antimicrobial peptide with immunomodulatory function as described above.

[0017] Beneficial effects and advantages of the present invention: The antimicrobial peptide Nap-FH6-Ubi 5-13 It can spontaneously assemble into a nano-mesh structure, has a good killing effect on Gram-negative bacteria in an acidic environment of pH 5.5, and has good biocompatibility. Although it has no antibacterial activity at pH 7.4, it captures pathogens and promotes the phagocytosis of cell clusters by macrophages. This can capture bacteria under neutral conditions and trigger the innate immune system to achieve antibacterial purposes, and can also break the membrane and kill bacteria in a weakly acidic environment, taking full account of the pathological acidic environment while avoiding the excessive use of antimicrobial peptides, effectively reducing the generation of drug resistance. 5-13 Antimicrobial activity and biocompatibility tests were performed and the antimicrobial peptide Nap-FH6-Ubi 5-13 In a weakly acidic environment, it has a significant inhibitory effect on Gram-negative bacteria such as Escherichia coli and Salmonella typhimurium, but has no significant effect on Gram-positive bacteria such as Staphylococcus aureus. 5-13 The maximum tested concentration did not show hemolysis under acidic and neutral conditions. 5-13 It is a pH-responsive self-assembling antimicrobial peptide with high application value. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 Antimicrobial peptide Nap-FH6-Ubi 5-13 Mass spectrum of

[0019] Figure 2 Antimicrobial peptide Nap-FH6-Ubi 5-13 chromatogram;

[0020] Figure 3 Antimicrobial peptide Nap-FH6-Ubi 5-13 The critical aggregation concentration and the linear fitting value graph of the critical aggregation concentration;

[0021] Figure 4 Antimicrobial peptide Nap-FH6-Ubi 5-13 Figure 1. Determination of hemolytic activity.

[0022] Figure 5 Antimicrobial peptide Nap-FH6-Ubi 5-13Cytotoxicity assay diagram; (a) cytotoxicity assay on IPEC J2 cells, (b) cytotoxicity assay on RAW 264.7 cells;

[0023] Figure 6 Antimicrobial peptide Nap-FH6-Ubi 5-13 Killing activity against common pathogens; (a) E. coli 25922, (b) E. coli K88, (c) S. typhimurium 7731, (d) S. typhimurium 14028, (e) S. aureus 43300, (f) S. aureus 29213;

[0024] Figure 7 Antimicrobial peptide Nap-FH6-Ubi 5-13 Determination of the ability to capture E. coli ATCC 25922 by sedimentation; (a) bacterial sedimentation graph, (b) colony count determination graph;

[0025] Figure 8 Antimicrobial peptide Nap-FH6-Ubi 5-13 Promote macrophage phagocytosis of E.coli 25922; Figure

[0026] Fig. 9 Antimicrobial peptide Nap-FH6-Ubi 5-13 Figure 2: Promoting macrophage phagocytosis of E. coli, including (a) Bright control group, (b) EGFP staining of control group, (c) DAPI observation of control group, (d) merged control group, (e) Nap-FH6-Ubi 5-13 Treatment group Bright, (f) Nap-FH6-Ubi 5-13 EGFP staining of treatment group, (g) Nap-FH6-Ubi 5-13 DAPI observation merge of treatment group, (h) Nap-FH6-Ubi 5-13 Processing group merge. DETAILED DESCRIPTION

[0027] The present invention is further described in detail below in conjunction with embodiments and drawings, but the embodiments of the present invention are not limited thereto.

[0028] Example 1

[0029] Antimicrobial peptide Nap-FH6-Ubi 5-13 Design

[0030] The polar uncharged phenylalanine and histidine with imidazole groups were arranged alternately to obtain the sequence structural unit of FH, which was repeated 6 times to construct a β-folded secondary structure with a hydrophilic-hydrophobic alternating mode. At physiological pH, the neutral imidazole group can act as both a hydrogen bond donor and a hydrogen bond acceptor, and can promote the self-assembly of the peptide chain molecules into a supramolecular nanostructure through hydrogen bonding with the hydrophobic amino acid phenylalanine to form a stable nanofiber structure; under weak acid pH conditions, the imidazole group undergoes H protonation, causing an increase in positive charge, and the positively charged polypeptide recognizes and is enriched on the surface of the negatively charged bacterial membrane to exert antibacterial activity; GGG is selected as a flexible linker to connect with the 5th to 13th active recognition region of ubiquitin VKTLTGKTI to construct a polypeptide sequence as shown in SEQ ID No.1, and then the N-terminus is acetylated with 2-naphthylbutyric acid Nap as a hydrophobic scaffold to provide hydrophobic forces, and finally a nano antimicrobial peptide with immunomodulatory function is constructed.

[0031] The amino acid sequence of the antimicrobial peptide is as follows:

[0032] Nap-FHFHFHFHFHFHGGGVKTLTGKTI

[0033] Table 1 Amino acid sequence

[0034]

[0035] The molecular structure is shown in formula (I):

[0036]

[0037] Example 2

[0038] Synthesis of Nano-antimicrobial Peptide Nap-FH6-Ubi by Solid-Phase Chemical Synthesis 5-13

[0039] 1. The preparation of antimicrobial peptides is carried out one by one from the C-terminus to the N-terminus, and is completed by a peptide synthesizer. First, Fmoc-X (X is the first amino acid at the C-terminus of each antimicrobial peptide) is connected to Wang resin, and the Fmoc group is removed to obtain X-Wang resin; then Fmoc-Y-Trt-OH (9-fluorenylmethoxycarboxyl-trimethyl-Y, Y is the second amino acid at the C-terminus of each antimicrobial peptide); synthesize from the C-terminus to the N-terminus in sequence as above until the synthesis is completed, and obtain a resin with the side chain protection of the Fmoc group removed;

[0040] 2. Add a cleavage agent to the peptide resin obtained above, react at 20°C in the dark for 2 hours, and filter; wash with precipitated TFA (trifluoroacetic acid), mix the washing liquid with the above filtrate, concentrate on a rotary evaporator, add about 10 times the volume of pre-cooled anhydrous ether, precipitate at -20°C for 3 hours, precipitate a white powder, centrifuge at 2500g for 10 minutes, collect the precipitate, wash with anhydrous ether, and vacuum dry to obtain a polypeptide. The cleavage agent is a mixture of TFA, water and TIS (triisopropylsilyl chloride) in a mass ratio of 95:2.5:2.5;

[0041] 3. Fmoc-S5-OH (1 mmol), HATU (1 mmol), HOAT (1 mmol), DIPEA (1 mmol) DMF (6 mL) was mixed for 15 min and then added to the resin at room temperature. After 2 hours, the resin was washed with DMF (3 times), DCM (3X, 5 mL) and DMF (3X, 5 mL) in sequence. The ring-closing metathesis reaction was carried out in 1,2-dichloroethane (DCE) at 35 °C using Grubbs' first-generation catalyst. The resin was washed with DCM (3X, 5 mL) and DCE (3X, 5 mL), and then treated with a 10 mM solution of Grubbs' first-generation catalyst in DCE;

[0042] 4. Use 0.2 mol / L sodium sulfate (phosphoric acid adjusted to pH = 7.5) to balance the column for 30 minutes, dissolve the polypeptide with 90% acetonitrile aqueous solution, filter, C18 reverse phase atmospheric pressure column, use gradient elution (eluent is methanol and sodium sulfate aqueous solution mixed in a volume ratio of 30:70 to 70:30), flow rate is 1 mL / min, detection wave is 220 nm, collect the main peak, and freeze-dry; further purify using reverse phase C18 column, eluent A is 0.1% TFA / water solution; eluent B is 0.1% TFA / acetonitrile solution, elution concentration is 25% B to 40% B, elution time is 12 min, flow rate is 1 mL / min, collect the main peak as above, and freeze-dry;

[0043] 5. Identification of polypeptides: The polypeptides obtained above were analyzed by electrospray mass spectrometry. The molecular weights shown in the mass spectra (see Appendix Figure 1 ) is basically consistent with the theoretical molecular weight in Table 1, and the purity of the polypeptide is greater than 95%.

[0044] Example 3

[0045] Antimicrobial peptide Nap-FH6-Ubi 5-13 Nanoscale characterization assays:

[0046] Critical aggregation concentration determination: To detect the antimicrobial peptide Nap-FH6-Ubi 5-13The ability to form nanostructures, critical aggregation concentration (CAC) was determined using 1-aniline-8-naphthalenesulfonic acid (ANS) fluorescent probe. 1 μL ANS (final concentration of 1 mM, dissolved in 100% DMF) was added to different concentrations of peptides (dissolved in deionized water of different pH values) and incubated at 37°C for 15 min. The mixed samples were transferred to a 96-well plate and the fluorescence spectrum was scanned using a fluorescence microplate reader with an excitation wavelength of 369 nm and an emission wavelength of 440 nm-550 nm. The CAC value of the peptide was then calculated using Origin software. The test results are shown in Figure 3 .

[0047] from Figure 3 (a, c) show that with the increase of concentration, the antimicrobial peptide Nap-FH6-Ubi 5-13 The fluorescence intensity gradually increased in the range of 440nm-550nm, indicating the presence of nano-macromolecules in the solution. The formation of nanostructures was preliminarily determined, and then the Origin software was used for fitting analysis. Figure 3 As shown in (b, d), Nap-FH6-Ubi 5-13 The CAC value at pH = 5.5 was 0.94 μM, and the CAC value at pH = 7.4 was 8.34 μM.

[0048] Example 4

[0049] Antimicrobial peptide Nap-FH6-Ubi 5-13 In vitro hemolytic activity, cytotoxicity and bactericidal activity assays:

[0050] 1. Hemolytic activity assay: Collect 1 mL of fresh human blood in a sodium heparin anticoagulant tube, centrifuge at 1000 g for 5 min to collect red blood cells, rinse with PBS 3 times and resuspend with 10 mL PBS, add different concentrations of peptides to a 96-well plate containing 50 μL PBS, and then add an equal volume of red blood cell suspension. The hRBC suspension treated with 0.1% Triton X-100 was used as a positive control, and the untreated hRBC suspension was used as a negative control. After incubation at 37°C in an incubator for 1 hour, take out and centrifuge at 4°C and 1000 g for 5 minutes; take out the supernatant and use an enzyme reader to measure the light absorption value at 570 nm, and the concentration that causes 5% hemolysis is the minimum hemolytic concentration.

[0051] Hemolysis results ( Figure 4 ) showed that the antimicrobial peptide Nap-FH6-Ubi 5-13 It has no hemolytic toxicity to human red blood cells.

[0052] 2. Cytotoxicity assay: The cells frozen in liquid nitrogen were revived and inoculated into a culture medium containing 10% fetal bovine serum and 1% double antibody, and subcultured at 37°C and 5% CO2. The cultured cells were digested with 0.25% trypsin and adjusted to 2-4×10 5 cells / mL. 50μL of cell suspension was mixed with 50μL of peptides of different concentrations in a 96-well plate and incubated at 37°C and 5% CO2 for 24h. Then 25μL of MTT (5mg / mL) was added to each well and incubated for another 4h. After the incubation, the supernatant was discarded, 100μL of DMSO was used to dissolve the crystals at the bottom of the well, and the absorbance of each well was measured at 570nm using an enzyme reader. The culture medium wells were used as blank controls. The test results are shown in Figure 5 .

[0053] from Figure 5 It can be seen that the antimicrobial peptide Nap-FH6-Ubi 5-13 There was no significant toxicity to IPEC J2 and RAW 264.7 cells, indicating that the antimicrobial peptide Nap-FH6-Ubi 5-13 It has good biocompatibility and has the potential to become an alternative to antibiotics.

[0054] 3. Determination of antibacterial activity:

[0055] In order to evaluate the antimicrobial peptide Nap-FH6-Ubi 5-13 The antibacterial effect of the antimicrobial peptides was determined by the microdilution method. Different concentrations of peptides were added to 0.2% BSA dilution (adjusted to pH = 5.5 with acetic acid) in a 96-well plate, and then an equal volume of 1×10 5 CFUmL -1 The final peptide concentration in a 96-well plate ranged from 0.25 to 128 μM. After incubation at 37 °C for 3 h, 50 μL was aspirated and serially diluted in PBS, and Nap-FH6-Ubi was counted by viable count method. 5-13 The number of colonies after treatment. See the test results Figure 6 .

[0056] Depend on Figure 6 It can be seen that in a weakly acidic environment, the antimicrobial peptide Nap-FH6-Ubi 5-13 It exhibits strong antibacterial activity against Gram-negative bacteria, but has lower antibacterial activity against Gram-positive bacteria.

[0057] Example 5

[0058] Antimicrobial peptide Nap-FH6-Ubi 5-13 Bacteria capture ability assay:

[0059] In order to evaluate the antimicrobial peptide Nap-FH6-Ubi 5-13 The ability to capture pathogens, OD 600 nm = 0.4 E. coli 25922 bacterial solution 3mL was placed in an ethanol-sterilized cuvette, and 16-256μM Nap-FH6-Ubi 5-13 The peptide solution was placed at room temperature for 6 hours, the bacterial agglutination state was observed and photographed, and the group without peptide treatment was used as the control group. 50 μL of bacterial supernatant was taken at 0, 0.5, 1, 2, 4, and 6 hours, and 450 μL of high-temperature sterilized PBS was added for gradient dilution. 100 μL of the dilution was evenly inoculated on the MHA plate culture medium. Incubate overnight in a 37°C incubator, count the number of colonies of each sample, and calculate the CFU value of each sample. The experiment was repeated three times, and the test results are shown in Figure 7 .

[0060] Depend on Figure 7 It can be seen that under neutral conditions, the antimicrobial peptide Nap-FH6-Ubi 5-13 It has a significant capture and sedimentation effect on E. coli 25922 in a concentration- and time-dependent manner. 256 μM antimicrobial peptide Nap-FH6-Ubi 5-13 A 1-hour treatment was sufficient to completely precipitate the E. coli.

[0061] Example 6

[0062] Antimicrobial peptide Nap-FH6-Ubi 5-13 Immunomodulatory capacity assay:

[0063] 1. Gentamycin protection test: To evaluate the antimicrobial peptide Nap-FH6-Ubi under physiological conditions 5-13 Whether it promotes the phagocytosis of bacterial clusters by macrophages, the bacterial content in macrophages was detected by gentamicin protection test. Take the E. coli 25922 bacterial solution in the logarithmic growth phase, centrifuge at 3000rpm for 5 minutes to collect the bacteria, wash them three times with PBS buffer, resuspend them in PBS buffer, and adjust the bacterial concentration to OD 600nm =0.4. Add 16μM and 32μM Nap-FH6-Ubi 5-13Co-culture with bacterial suspension at 37°C for 2 hours. Add the bacterial particles pretreated with peptides to the cell culture medium of RAW 264.7, culture at 37°C for 2 hours, remove the cell culture medium and wash 3 times, add 50μg / mL gentamicin solution to remove extracellular bacteria, use 0.1% Triton X-100 to lyse for 10 minutes, aspirate 50μL lysate, add 450μL high-temperature sterilized PBS for gradient dilution, take 100μL dilution and evenly inoculate on MHA plate culture medium. Culture overnight in a 37°C incubator, calculate the colony count (CFU) of each sample, repeat the experiment three times, and the test results are shown in Figure 8 .

[0064] from Figure 8 It can be seen that compared with the control group, 16μM and 32μM of the antimicrobial peptide Nap-FH6-Ubi 5-13 After pretreatment, the internalization of E. coli particles in RAW 264.7 was significantly increased in a dose-dependent manner (the significant value in the figure is a with a large value). This indicates that the antimicrobial peptide Nap-FH6-Ubi 5-13 Capable of capturing bacteria and further enhancing the phagocytic ability of phagocytes.

[0065] 2. Macrophage phagocytosis of bacteria: In order to visually observe the antimicrobial peptide Nap-FH6-Ubi 5-13 To promote the phagocytosis of bacterial clusters by macrophages, we used a fluorescent inverted microscope to observe the phagocytosis of Escherichia coli by RAW 264.7. Prepare E. coli particles containing green fluorescent protein, collect the E. coli cells by centrifugation at 3000rpm for 5 minutes, and resuspend them in PBS buffer. Add a peptide solution with a final concentration of 16μM and co-culture with the bacterial suspension at 37°C for 2 hours. Add the bacterial particles pretreated with peptides to the cell culture medium of RAW 264.7, culture at 37°C for 2 hours, aspirate the cell culture medium and wash 3 times, add Triton X-100 to fix for 10 minutes, aspirate Triton X-100 and wash 3 times, and add an anti-fade agent containing DAPI. Observe with a fluorescent inverted microscope. The test results are shown in Fig. 9 .

[0066] The results are as follows Fig. 9 As shown, compared with the control, the antimicrobial peptide Nap-FH6-Ubi 5-13 The treated E. coli particles aggregated, and the phagocytosis of aggregated E. coli particles by RAW 264.7 macrophages was enhanced, indicating that the nanocapture peptides were able to capture bacteria and further promote the uptake of phagocytes.

[0067] Therefore, the antimicrobial peptide Nap-FH6-Ubi 5-13It can capture bacteria under neutral conditions and trigger the innate immune system to achieve antibacterial purposes, and it can also break the membrane and kill bacteria in a weakly acidic environment. It fully takes into account the pathological acidic environment while avoiding the excessive use of antimicrobial peptides, effectively reducing the development of drug resistance and mobilizing the body's immune function to synergistically resist bacterial infections.

Claims

1. A pH-responsive nano antimicrobial peptide with immunomodulatory function, characterized in that: Its amino acid sequence is shown in SEQ ID No. 1, and its N-terminus is acetylated by 2-naphthoic acid.

2. The pH-responsive nano antimicrobial peptide with immunomodulatory function according to claim 1, characterized in that: Its molecular formula is shown in formula (I):

3. The pH-responsive nano antimicrobial peptide with immunomodulatory function according to claim 1, characterized in that: The self-assembly conditions are as follows: pH=5.5, concentration 1-256 μM, incubation at 37°C for 24 hours or pH=7.4, concentration 9-256 μM, incubation at 37°C for 24 hours.

4. The pH-responsive nano antimicrobial peptide with immunomodulatory function according to claim 1, characterized in that: In an acidic environment of pH 5.5, Escherichia coli or Salmonella typhimurium can be killed, and in an acidic environment of pH 7.4, Escherichia coli can be captured.

5. The method for preparing a pH-responsive nano antimicrobial peptide with immunomodulatory function according to claim 1, characterized in that: The steps are as follows: S1: Alternately arrange polar uncharged phenylalanine and histidine with imidazole groups to obtain the sequence structural unit of FH and repeat it 6 times to construct a β-folded secondary structure with a hydrophilic-hydrophobic alternating pattern, select GGG as a flexible linker to connect with the 5th to 13th active recognition region VKTLTGKTI of ubiquitin, and construct the sequence of the polypeptide as shown in SEQ ID No. 1, and then acetylate its N-terminus with 2-naphthoic acid to provide hydrophobic interaction as a hydrophobic scaffold; S2: Synthesize by solid phase chemical synthesis, and then complete the preparation of the peptide after chromatography purification and mass spectrometry identification; S3: The peptide was then subjected to nanomorphological characterization, biocompatibility, capture ability, antibacterial ability, and macrophage phagocytosis ability tests, and was finally named the antimicrobial peptide Nap-FH6-Ubi 5-13 .

6. Use of a pH-responsive nano antimicrobial peptide with immunomodulatory function according to claim 1 in the preparation of a drug for treating and / or preventing diseases caused by Gram-negative bacteria.

7. The use according to claim 6, characterized in that: The Gram-negative bacteria are Escherichia coli or Salmonella typhimurium.

8. A drug for treating and / or preventing Gram-positive bacterial infection, wherein the Gram-negative bacteria are Escherichia coli or Salmonella typhimurium, characterized in that: The medicine contains the pH-responsive nano antimicrobial peptide with immunomodulatory function as described in claim 1.

Citation Information

Patent Citations

  • pH regulation self-assembled antibacterial peptide and preparation method and application

    CN111777670A

  • Compositions for prevention of adhesions and other barrier applications

    US20080032934A1